About /

MSDC was founded in 2006 by Jerry Colca, PhD and Rolf Kletzien, PhD, former researchers at The Upjohn Company who pioneered the early development of insulin sensitizers for type 2 diabetes and who selected and led the early development of Actos® (pioglitazone).

The vision of the company’s founders – that diabetes can and should be prevented — and their pioneering insights into the pharmacology of insulin sensitizers has driven MSDC to the forefront of the field with the breakthrough discovery of a new drug target for metabolic diseases located in the inner mitochondrial membrane, mTOT™.

MSDC is dedicated to bringing new hope to patients for the treatment and prevention of age-related metabolic diseases, and the company’s novel class of insulin sensitizers, called mTOT Modulators™, are already in clinical trials involving patients diagnosed with type 2 diabetes and Alzheimer’s disease.

MSDC’s headquarters and laboratories are located in Kalamazoo, Michigan.